DK
Therapeutic Areas
Dr. Reddy's Laboratories Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Generic Semaglutide Injection (Obeda) | Type 2 Diabetes | Approved |
| Generic Semaglutide (Oral) | Type 2 Diabetes, Obesity | Development |
| Bevacizumab Biosimilar | Various Cancers | Approved |
| Rituximab Biosimilar | Non-Hodgkin Lymphoma, Rheumatoid Arthritis | Approved |
| Lenacapavir | HIV-1 Infection | Approved |
| Toripalimab | Recurrent/Metastatic Nasopharyngeal Carcinoma | Approved |
| CAR T-Cell Therapy Program | Relapsed/Refractory Multiple Myeloma | Development |
| Injectable Contraceptive | Women's Health / Family Planning | Development |
Leadership Team at Dr. Reddy's Laboratories
EI
Erez Israeli
Chief Executive Officer
DS
Deepak Sapra
CEO, API & Services
MR
M.V. Ramana
CEO, Branded Markets
DM
Dr. Murali Ramachandra
Chief Executive Officer, Aurigene Oncology
KV
Krishna Venkatesh
Global Head of Quality and Pharmacovigilence